< Back to Press Releases
Wolfe Laboratories Appoints New Vice President of Pharmaceutical Science
WATERTOWN, MA — January 5, 2012 — Wolfe Laboratories, Inc., an integrated early biopharmaceutical development services company, announced the appointment of David Casebier, Ph.D. to the position of Vice President of Pharmaceutical Sciences.In his new position, Dr. Casebier will be responsible for strategic programs in R&D, focusing specifically on the innovation and growth of Wolfe’s proprietary analytical and formulation technology platforms.
“We are excited for David to join Wolfe’s team,” commented Janet Wolfe, Ph.D., Founder and President of Wolfe Laboratories. “His proven ability to form and lead technically innovative teams is particularly timely as demand for Wolfe’s services increases amongst large biopharmaceutical companies. As Wolfe expands its capabilities in the areas of complex small molecule dosage forms, biologics, biosimilars, and targeted therapeutics, David’s wealth of drug development experience will accelerate the flow of technical innovation through the pipelines of our clients.”
Most recently, Dr. Casebier served as the Senior Vice President for Pharmaceutical Sciences at Tokai Pharmaceuticals, where he successfully oversaw the formulation, development, and manufacturing of a novel therapeutic for prostate cancer. Previously, Dr. Casebier was Senior Director of Chemistry at Lantheus Medical Imaging, formerly a division of Bristol-Meyers Squibb (BMS). While at BMS, he was responsible for all aspects of chemistry from project conception to commercial launch, including medicinal chemistry and active pharmaceutical ingredient (API) manufacturing. Prior to joining BMS, Dr. Casebier was the first employee at ArQule, where he built the automated combinatorial chemistry capability of the company. During his tenure at ArQule, he held positions of increasing responsibility at the Director, then Vice President level, ultimately managing a subsidiary focused on materials research using ArQule technology.
Dr. Casebier holds a B.S. in chemistry from Washington State University and a Ph.D. from the Massachusetts Institute of Technology. David was an NIH Postdoctoral Fellow at Brown University, where he worked on biosynthesis of polyketide macrolides. Dr. Casebier is the holder of 16 patents, author of numerous peer-reviewed publications, and recipient of leadership and scientific awards.